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Abstract
Background: Health care planning depends upon good knowledge of prevalence that requires a clear understanding of
survival patterns of patients who receive medication, treatment and care. Survival analysis can bring to light the effect
that some demographic, social, medical and clinical characteristics have on the mortality rate of HIV-patients.
Objectives: The objective of this research undertaking was to estimate mortality rate and identify predictors that have
significant impact on the survival status of a sample of patients who received antiretroviral treatment and care in  Tikur
Anbessa Specialized Hospital, Addis Ababa, Ethiopia.
Methods: The data for this research were collected during the follow-up time from 2005 to 2008. Out of a population
of HIV-patients who were taking antiretroviral therapy in the hospital in that period, data on 1,000 patients were used
for this study. The study subjects were people in the age range from 15 to 75 years. The Kaplan-Meier Method was
employed to estimate mortality; the Cox Proportional Hazards Regression Method was used to identify determinants
of mortality.
Results: After initiation of the antiretroviral treatment, HIV-positive patients lived for an average of 5.65 years (CI:
3.69-7.61 years); the median survival age was found to be 3.98 years (CI: 2.98-4.97 years). The number of
medications, baseline functional status, CD4 count, antiretroviral treatment, age, gender and weight impact the
survival experience of the patients.
Conclusions: Antiretroviral therapy treatment reduced death among AIDS patients by 50 percent. Providing treatment
at health facilities outside big towns and in the country should be given due attention. Similar studies in the future need
to consider predictors in addition to those considered in this study. [Ethiop. J. Health Dev. 2012;26(1):22-29]
Introduction
Studying the history of disease progression due to
HIV/AIDS and the treatments are useful for the purpose
of developing treatment guidelines, modeling the
epidemic and prioritizing and allocating resources.
Health care planning depends on good knowledge of
prevalence, which requires an accurate understanding of
survival patterns. Monitoring the length of survival after
diagnosis is, therefore, an important component of the
surveillance of AIDS. It provides a basis for evaluating
individual prognostic factors. In addition, differences in
survival may also reflect differences in access to health
care (e.g. access to testing, counseling, preventive
treatment). The survival of patients with AIDS may
depend on a variety of factors including host factors, the
patterns of diseases present, access to health care,
diagnostic routines and therapeutic interventions (1).
Long-term sustainable treatment is one choice for people
living with HIV. Not only can medications slow the
progression of the infection, but can also markedly
suppress the virus, thereby restoring the body’s immune
function and permitting many HIV-infected individuals
to lead a normal life. People living with HIV take a
number of medications like cotrimoxazole, fluconazole,
INH and other medications depending on the type of the
opportunistic illness they have.
Even though AIDS drugs have become cheaper and more
available because of a variety government and private
programs, millions of others still do not have access to
the drugs. WHO recommends that in resource-limited
settings HIV infected adolescents and adults should start
ART when the following conditions are met: WHO stage
4 regardless of CD4 count, stage 3 disease with
consideration of CD4 count below  350/mm3 in assisting
decision making, stages 1 or 2 diseases with CD4 cell
count below 200/mm3. In a setting where CD4 count is
not available, the total lymphocyte count (TLC) can be
used, and treatment is recommended for WHO stages 3
or 4 (clinical AIDS) irrespective of the TLC and stage 2
with TLC not exceeding 1200/mm3.
Pre-antiretroviral therapy includes guidelines that attempt
to address factors which are important in the holistic
approach to patient management which could also
influence the progression and outcome of disease
including natural history of HIV infection, primary
prophylaxis and immunization, nutrition, support and
counseling (2).
Survival patterns following HIV infection in African
populations in the era before antiretroviral therapy (ART)
form an important baseline for measuring future
successes of treatment programs (3). According to (4)
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nearly 3 million people in low- and middle-income
countries were receiving ART treatment. That is a 10-
fold jump compared with some 300,000 taking drugs
acquired for immunodeficiency syndrome (AIDS) in the
year 2003.
Knowledge of the survival times of patients with AIDS
and variables that influence survival are important both
for increasing understanding of the patho-physiology of
the disease, clinical decision making and planning health
service interventions (5). The main challenge here is the
sustainability of providing ART and other medications at
district hospitals. About one million people were living
with HIV in Ethiopia in the year 2008 (6).
A lot of effort has been made to improve the health
quality of HIV-positive patients in Ethiopia and extend
the time interval from HIV-infection/AIDS-diagnosis to
death. For instance, activities like prevention of the
disease through effective use of prophylaxis, intervention
strategies and awareness raising such as mass media
campaigns, peer education about HIV transmission,
treatment of other sexually transmitted infections, safe
blood transfusion provision, and prevention from mother
to child treatment have been taken.
Despite the availability of a large body of research
evidence that addresses issues about AIDS in Ethiopia,
the level of understanding about predictor variables
associated with mortality rate as a result of HIV infection
is low. This study was undertaken with objectives to
estimate mortality and identify predictors that have
impact on the survival of HIV-positive patients with the
hope that the results would contribute to existing
knowledge.
Methods
The survival data for this study were obtained from Tikur
Anbessa Specialized Hospital, a teaching hospital in
Addis Ababa associated with the School of Medicine of
the Addis Ababa University. The ART unit in the
Hospital provides general voluntary counseling and
testing services, follow up, pre-antiretroviral and ARV
service for people living with HIV/AIDS. At the
Hospital’s ART clinic the data were recorded using the
standardized data collection formats and registers
prepared by the Ministry of Health.  Data recording was
done by health officers and nurses working in the clinic.
The examining medical doctors also recorded follow up
information about their patients.
Data recording starts from the date patients started HIV-
regular care in the clinic till it was confirmed that
patients have experienced one of the events - “death”,
“lost to follow-up”, “dropped from the clinic”, “stopped”,
and “transferred out to other health centers”. Information
on patients who had been transferred to the clinic were
also recorded after reviewing their past history from the
referring hospitals or heath centers. In this process the
names of patients, initials or hospital initials had been
removed adhering to national and international ethical
standards.
The database for this study included patients of age from
15 to 75 years who had come to the clinic from the year
2005 to 2008. Even though the number of patients who
took the treatment during this time period was large,
complete information on the clinical variables chosen for
this study could not be obtained for all; this is
particularly true in the early years of introduction of the
treatment. Hence, a decision was reached to base this
study on 1000 patients for whom complete information
was available; this size was desirable to obtain reliable
results in survival analysis. In addition to that, time
constraint and the cost of data collection dictated this
research to consider the above-mentioned sample size. In
this connection, it is important to point out that some
important clinical variables were poorly documented in
the ART unit at the time when data collection for this
study was done.
The process of data collection for the research involved
Distributing data collection formats to the experts in the
clinic; checking whether the formats were filled
correctly, and entering the correct data into computer.
The data were stored in Excel, and then imported to
SPSS, SAS and Stata for further analysis. Most of the
Descriptive Analysis was done using SPSS software; the
proportional hazards regression analysis was performed
using SAS and STATA software.
Variables of the study: The response variable in this
research that was the “survival time” was defined as the
number of days from the date of enrollment of a patient
in the HIV-care till one of the events “death”,  “lost to
follow up”, “dropped out”, “stopped”, “transferred out to
other health centers or hospitals” occurred. This meant
that the survival data studied here were “right-censored”.
The predictor variables relate to the social, demographic,
medical and clinical background of the patients having
these respective classifications; age (in full years), gender
(male, female), marital status (never married, married,
separated, divorced, widowed), religion (Muslim, Coptic
Orthodox, Protestant, Catholic, others), weight (in
kilograms), functional status (working, ambulatory,
bedridden), WHO clinical stages (stage 1, stage 2, stage
3, stage 4),  number of medications taken (0,1, 2, 3, 4),
CD4 cell count (in mm3), and highly active antiretroviral
therapy (HAART) (yes, no).
The statistical analytic method used in this study is
known as Survival Analysis. Survival data analysis
involves the modeling and analyses of data that have a
principal end point - the time until an event occurs (time-
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to-event data). Survival Analysis considers conditional
information on the remaining time of a subject’s survival
given current survival time. Survival data were censored
in the sense that they did not provide complete
information since, for a variety of reasons, subjects of the
study may not have experienced the event of interest. The
existence of variables that change over time is also a
distinguishing feature in survival analysis.
Descriptive analysis of survival data utilizes non-
parametric methods to compare the survival functions of
two or more groups. The Kaplan-Meier estimator
(product-limit-estimator) of the survival function (7) was
employed for this purpose. The log-rank test was utilized
to test whether observed differences in survival
experience between/among the groups was significant or
not.
The multivariable model used was the semi-parametric
regression model known as the proportional hazards
regression (PHR) model (8). When a study involves
multiple characteristics, appropriate statistical techniques
must be used to select variables that have significant
effects on survival and which are judged to be clinically
meaningful for inclusion in a PHR model. Hence, the
model development process identifies the relevant
variables following model scrutiny as discussed in (9).
Results
Results of the descriptive analysis: This study used
observations on 1000 HIV-positive people that were
followed during 2005 to 2008. Of those, about 90% were
right-censored and the remaining uncensored. HIV-
positive patients lived for an average of 5.65 years (CI:
3.69-7.61 years); the median survival age was found to
be 3.98 years (CI: 2.98-4.97 years).
A summary of the data for each level of variables is
provided in Table 1. Table 2 gives results based on the
log-rank test. The p-values in Table 2 show differences in
survival experience between two or more levels of
predictors. All predictors with the exception of marital
status, religion and age manifest differences in levels of
survival functions. A résumé emanating from descriptive
analysis with reference to the seven predictors (leaving
out marital status, religion and age) that manifest
differences in survival are provided as follows.
Males live for an average of four years longer than
females. Patients who were working lived on average one
year and two years longer than those in ambulatory and
bedridden conditions, respectively. The number of
medications had direct or indirect association with the
existence of the number of opportunistic infections (OIs).
Patients, who took one medication, had longer survival
time than others living on average:  four years longer
than patients who took no or two medications; five years
longer than those who took three and four medications.
Taking four medications was associated with the lowest
survival time. HIV-positive patients, with WHO clinical
stage 1 had an average of two years longer survival time
than those in stages 2, 3 and 4. Those patients in clinical
stages 2, 3 and 4 had (more or less the same) three years
survival time. Patients, who were eligible for ART, but
had not taken the therapy, had a shorter survival time;
which was on average five years shorter than those
receiving ART. Patients having weights 45 to 54
kilograms lived four years longer on average than those
having weight in the range of 55 and 80 kilograms.
Patients, who weighed 20 to 34 kilograms and 35 to 44
kilograms, respectively, lived five and six year shorter on
average compared with those people who had weights in
the  range  45  to 54  kilograms.  Those having CD4 cell
count above 200/mm3 lived three years longer on average
than patients with CD4 cell count below 200/mm3.
Results of the PHR model: The Cox model procedure
that includes model selection, tests, diagnosis and fit
confirmed that there were no problems with regard to
interactions of main effects and confounding.  Therefore,
the results in Tables 3 and 4 are based on the main
effects; the model is sometimes called the crude
(unadjusted) model. Because age is such a demographic
variable that could influence survival status, it was
brought into the multivariable model, and was found to
be significant. The following elaboration details survival
experience based on estimated crude hazard ratios (HR)
in Table 4. It should be pointed out that variables with p-
values below 0.05 were considered as statistically
significant.
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Table 1: Socio-demographic and clinical characteristics of HIV-positive patients at ART initiation in
Tikur Anbessa Specialized Hospital, Addis Ababa, 2005-2008, (n =1000).

























































































































































































Table 2: Log-rank test p-values based on socio-demographic and clinical
characteristics data of HIV-positive patients at ART initiation in Tikur Anbessa
Specialized Hospital, Addis Ababa, 2005-2008, (n =1000).
Variable Df Chi-sq Log-Rank
Test p-Value
Gender 1 3.80 0.04
Marital Status 4 8.26 0.08
Religion 4 2.57 0.63
Functional status 2 16.69 <0.0001
Number of medication 4 32.87 <0.0001
WHO clinical stages 3 9.69 0.02
ART 1 11.14 0.001
Age 3 3.48 0.32
Weight 3 15.58 0.001
CD4 count/mm3 1 7.85 0.04
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Table 3: Estimated parameters for the preliminary Proportional Hazards Regression Model
Containing variable significant at 20% level in the bivariate analysis for the data from






Gender 1 -0.435 0.230 3.567 0.059
Age2 1 0.799 0.289 7.609 0.006
Age 3 1 0.459 0.336 1.864 0.172
Age 4 1 1.473 0.595 6.137 0.013
Marital 0 1 0.148 0.263 0.316 0.574
Marital 2 1 0.665 0.616 1.166 0.280
Marital 3 1 -0.661 0.382 2.994 0.084
Marital 4 1 -0.360 0.345 1.088 0.297
Function 1 1 0.274 0.258 1.132 0.287
Function 2 1 1.153 0.294 15.374 <.0001
Nummedic 1 1 -0.987 0.250 15.532 <.0001
Nummedic 2 1 -0.389 0.317 1.504 0.220
Nummedic 3 1 -1.788 0.533 11.242 0.001
Nummedic 4 1 1.078 0.415 6.758 0.009
WHO1 1 0.388 0.754 0.265 0.607
WHO2 1 -0.904 0.614 2.170 0.141
WHO3 1 0.288 0.224 1.643 0.200
ART 1 -0.662 0.219 9.098 0.003
CD4 1 -0.002 0.001 3.519 0.061
Weight 1 -0.042 0.011 13.791 0.000
Socio-demographic characteristics: The estimated HR
for females was 0.55 (CI: 0.365-0.843), meaning that
males were dying at a rate of 45% lower than females.
The referent category for age was the age group from 15
to 29 years. The estimated HRs for the age groups (30-
44] and (60-75] were 1.65 (CI: 1.080-2.514) and 2.86
(CI: 1.006-8.140), respectively. As age the group (45-59]
was insignificant (see Table 3 at 0.05 level) it was
excluded. For bedridden patients, the estimated HR was
2.67 (CI: 1.661-4.305) as compared to the referent
category “working”. The status of being ambulatory did
not have a significant contribution at 0.05 level (see
Table 3). That is why it is not included in the final model.
A 5 kilogram increase in weight resulted in an estimated
HR of 096 (CI: 0.994-0.984).
Clinical characteristics: The referent category pertaining
to the number of medications was the group not taking
any medications. The estimated HRs for those taking
one, three and four medications, respectively, are 0.46
(CI: 0.301-0.715), 0.21 (CI: 0.075-0.580) and 4.06 (CI:
1.869-8.823). The category of the two medications was
not included according to the 0.05 level exclusion rule
(see Table 3). The estimated hazard ratio for ART was
0.50 (CI: 0.328-0.757) relative to the category not taking
ART. A 10/mm3 increase in CD4 count was associated
with a HR 0.98 (CI: 0.996-0.999).
Table 4: Estimated parameters for the final Proportional Hazards Regression Model for the data from Tikur Anbessa
Specialized Hospital, Addis Ababa, 2005-2008, (n =1000).
Variable df Parameter
Estimate
Std. Er. Chi-Sq Pr>Chi-Sq HR
Estimate
95% CIE for HR
Gender 1 -0.589 0.214 7.616 0.006 0.55 0.365       0.843
Age2 1 0.500 0.215 5.378 0.020 1.65 1.080       2.514
Age4 1 1.051 0.533 3.888 0.039 2.86 1.006       8.140
Function 2 1 0.984 0.243 16.385 <.0001 2.67 1.661       4.305
Nummedic 1 1 -0.768 0.221 12.100 0.001 0.46 0.301       0.715
Nummedic 3 1 -1.569 0.523 9.005 0.003 0.21 0.075       0.580
Nummedic 4 1 1.401 0.396 12.529 0.000 4.06 1.869       8.823
ART 1 -0.697 0.214 10.627 0.001 0.50 0.328       0.757
CD4 1 -0.002 0.001 4.278 0.039 0.98 0.996       0.999
Weight 1 -.037 0.011 12.368 0.000 0.96 0.944       0.984
Note: The categories and status of some of the predictors are as follows: age 1(15-29 years), age 2 (30-44 years), age 3 (45-
59 years), age 4 (60-75 years); function 1 (working),  function 2 (ambulatory), function 3 (bedridden); nummedic 0 (no
medication), nummedic 1 (taking one medication), nummedic 2 (taking two medications), nummedic 3 (three medications),
nummedic 4 (four medications).
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Figure 1: Overall Survival and hazard functions (in days)
Discussion
Female HIV-positive patients had shorter survival on
average compared to males.  It was observed that the
survival time of patients under ART varied along
differences in functional status. Bedridden patients had
the least survival time. Patients, who took one medication
lived longer on average than those who took two, three
and four medications. Patients who took four medications
had the least survival time. Those weighting in between
45 kg and 54 kg lived longer on average than those
weighting between 35 and 44 kg. Those weighting
between 20 kg and 34 kg had on average better survival
experience than patients in the weight group 35 kg and
44 kg. People living with HIV/AIDS under ART had
better survival time on average than patients who were
eligible for ART, but did not take the treatment. CD4
cells counts showed a strong influence on the survival
status; patients with counts of more than 200/mm3 had
higher survival experience than those with counts below
200/mm3. Increasing in CD4 count is achieved through
ART. Comparison of survival estimates by treatment
groups suggested that there were significant differences
in the survival status with regard to the number of
medications taken.
Gender has a significant influence on survival (10).  The
association of gender with survival is found not to be
significant (3, 11, 12). Contrary to (13), the situation
where it was showed that males are in a higher risk of
death compared to females, this study shows that females
experienced higher mortality rate than males.
Results in (3, 12) showed that survival is strongly related
to age. The results of (13) suggest that survival is
independent of age. This study has also come up with
similar conclusions as in (3, 12).
Low ability to attain self-sufficiency in the requirements
of daily living (ADLs) related to shorter survival (14,
15). The findings of this study showed (13) ambulatory
and bedridden patients, respectively, were 82.5% and
nearly four-and-half times more likely to die compared to
those working. The study also showed that bedridden
patients were more than two-and-half times likely to die
than those patients engaged in work.
People living with HIV take a number of medications
depending upon the number of opportunistic infections
that exist in their body. In this connection (16) the study
showed that mortality increased because of stopping one
of the medications, namely Cotrimoxazole (CTX). The
study indicated that HIV-positive people taking no
medication were at higher risk of dying.  Those who were
taking four medications were likely to die at a rate which
was about 4.06 times higher than patients who took no
medications; this rate could be as much as 8.82-fold or as
little as a 1.87-fold.
The findings of the study (13, 17, 18, 19) showed that
patients taking HAART lived longer. HAART reduced
mortality by 65% (19). A mortality decline of 49.3% was
observed (13). This study reached the same conclusion as
others mentioned here, and showed that the rate of
reducing of mortality was 50%. Taking ART could
increase longevity by a median survival time of 41
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months (18). According to this study, the median survival
time was 3.98 years was almost 48 months.
The studies (12, 13, 20, 21) showed that CD4 count is a
laboratory predictor of mortality in the sense that higher
CD4 counts are associated with longer survival time. The
current study concurs with conclusions above.
Weight loss is a cause for reduced longevity (22, 23).
This study agrees with the foregoing conclusion; it also
shows that a 5kg weight gain reduces mortality by 7
percent.
Conclusions and Recommendations
The study revealed that after initiation of the treatment,
HIV-positive people lived on average 5.65 years with
median survival time estimated to be nearly 4 years.
From among the variables included in the study, three of
them (religion, marital status and WHO clinical stages)
did not have significant impact on survival. The number
of medications, baseline functional status, CD4 count,
antiretroviral treatment, age, gender and weight had
significant impact on the survival experience of patients.
Females lived shorter than males. Patients, who were
working lived longer compared to ambulatory or
bedridden patients. The number of medications had
significant influence on the length of survival; taking
four medications was strongly associated with shortest
survival, while higher body weight did not indicate
longer survival, whereas low weight was not necessarily
associated with shorter survival. Older age was
associated with higher risk of death. ART improved the
quality of life of HIV-positive people. Higher CD4 cell
counts (>200/mm3) were observed to have an association
with better survival experience. Antiretroviral treatment
had changed the health status of the HIV-positive people
by prolonging the survival time of victims. The treatment
reduced deaths among AIDS patients by 50%.
The Ethiopian Health Policy should focus on thorough
and integrated primary health care with emphasis on
community-based services. The Health Service Extension
Program introduced in 2004 is intended to bring the
health services closer to the people. According to the
package, health centers and district hospitals have the
duties to provide HIV care, medications and treatment
including ART. It is therefore, encouraging to observe
that the Integrated Management of Adolescent and Adult
Illness (IMAI) developed by WHO providing practical
guidance on decentralized and integrated delivery of HIV
care is being used. In this regard, the main challenge
remains to be the sustainability of providing ART and a
number of the medications at district hospitals.
As the literature on survival and mortality of AIDS
patients points out, predictors related to nutrition, body
exercise, levels of income and social condition are
associated with survival. Similar future research
undertakings should seek to identify additional
characteristics (social, economic, behavioral, nutritional,
environmental, and the like) that may affect the mortality
rate of HIV-positive patients receiving ART service.
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